|| Print ||
|Archives - February 2009|
|Sunday, February 01, 2009|
In the race to cure malaria, the devastating disease that claims 1 million lives each year, every development is critical. The deadliest strain has grown increasingly resistant to chloroquine, the safest and cheapest anti-malarial drug available. The parasite that carries the virus has developed a “siphon” to purge the drug from itself. But instead of developing a new drug, a lengthy and costly process, Portland State University professor David Peyton and his research team at DesignMedix are re-engineering the original. These “reversed chloroquines” block the parasite’s siphon, killing the parasite. Some of these molecules are 10 times more effective than chloroquine alone, decreasing the required dosage significantly. Smaller doses could mean fewer side effects and lower manufacturing costs, Peyton says. The drug is expected to move to human trials in the next two to three years. Peyton sees the eradication of the disease as critical to the health of women and children, and for the health of malaria-stricken countries. “What the world needs now,” Peyton says, “is very good, very safe, very cheap anti-malarial drugs.”
Thursday, October 02, 2014
More than 5,500 employees from 180 organizations throughout the state participated in the 100 Best Nonprofits to Work for in Oregon project.
Friday, October 17, 2014
BY TOM COX | OB BLOGGER
How can you move from a command-and-control leadership model to one of true empowerment and accountability? David Marquet did, and he took notes along the way.
Wednesday, October 22, 2014
Peter Lizotte at ACME Business Solutions and Roger Busse at Pacific Continental Bank share their favorite reads.
Monday, November 10, 2014
BY KIM MOORE | OB RESEARCH EDITOR
A market for low-carbon transportation fuels has a chance to flourish in Oregon if regulators adopt the second phase of the state’s Clean Fuels Program.
Sunday, October 12, 2014
BY LINDA BAKER
Cylvia Hayes, tabloid vs. watchdog journalism and the looming threat of a Cascadia earthquake.
Monday, September 29, 2014
BY LINDA BAKER | OB EDITOR
Wehby disappears, Kitzhaber fails to disclose and Seattle gets bike share before Portland.
Tuesday, October 14, 2014
BY JONATHAN FROCHTZWAJG
A flare-up in the Elliott Forest raises questions about détente in Oregon’s timber wars.
|A Complex Portrait: Immigration, Jobs and the Economy|
|Woman of Steel|
|Kill the Meeting|
|Price of already-built homes in Seattle area drops|
|Apple hits record-high value|
|Fed's ability to regulate questioned|
|Budweiser to move away from Clydesdales|
|Mergers lucrative for departing CEOs, but not necessarily shareholders|
|Senators ask, but get no real answers regarding safety from air bag executives|
|Senate investigation says Wall Street misused commodities businesses|
Is your business ready to join us in the call for action? This opening panel includes Oregon businesses who will discuss why they signed the Oregon Climate Declaration, the investments they are making to reduce carbon emissions, and how their actions are affecting their companies.
Get ready for two days of special events produced with the EPA, Portland Timbers and ISOS before and after the GoGreen Conference on October 16.
Plenty of employers seem “dazed and confused” after the recent vote to legalize marijuana. In light of Measure 91 passing, what are some issues for private-sector Oregon employers to consider?
Rotary’s Oregon Ethics in Business aims to raise consciousness about business ethics by honoring exceptional companies.
Barran Liebman’s annual employment law seminar is an industry classic.
Is my drug-free workplace policy up in smoke?
More than 400 "Change Makers" will gather to invest in a socially sustainable community.